Clinical trial · Interventional
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Undifferentiated thyroid cancer is the most malignant tumor of the thyroid gland, with a median survival of only 3 months. Most undifferentiated cancers lose the chance of surgery when they are first diagnosed. The current study, Nexavar, is used only for dedifferentiated thyroid cancer and has not been applied to undifferentiated cancer. This study attempted to apply it to preoperative treatment of undifferentiated cancer to see if it would shrink the tumor and give the patient an opportunity for surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer, Anaplastic | Thyroid Gland Anaplastic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| External radiation therapy | Radiation | — | UNRESOLVED |
| Nexavar | Drug | — | UNRESOLVED |
| operation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nexavar neoadjuvant treatment group
- description
- After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed. operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue. then External radiation therapy after surgery.
- interventionNames
- Drug: Nexavar
- Procedure: operation
- Radiation: External radiation therapy
Primary outcomes (5)
- measure
- Thyroglobulin
- timeFrame
- Change from Baseline Blood Thyroglobulin at 1 month, 2 months, 3 months after treatment with NEXAVAR
- description
- Thyroglobulin
- measure
- CT assessment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Undifferentiated or poorly differentiated thyroid cancer * Tumor invades the trachea, esophagus or common carotid artery that are Unresectable. * Locally recurrent anaplastic thyroid cancer * The lesion size is greater than 3cm * Patients in whom the oncologist has decide to start therapy with NEXAVAR. Exclusion Criteria: * Lesions cannot be evaluated by imaging * Synonymous with contraindications to Nexavar.
References
Publications (0)
Data not yet available